Get the Stockscreener App
508.90
0.73%
-3.75
After Hours:
508.90
Overview
News
Price History
Option Chain
Financials
Why TMO Down?
Discussions
Forecast
Stock Split
Dividend History
Thermo Fisher Scientific Inc stock is traded at $508.90, with a volume of 1.54M.
It is down -0.73% in the last 24 hours and down -4.46% over the past month.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).
See More
Previous Close:
$512.65
Open:
$512
24h Volume:
1.54M
Relative Volume:
0.84
Market Cap:
$191.99B
Revenue:
$42.88B
Net Income/Loss:
$6.34B
P/E Ratio:
30.79
EPS:
16.53
Net Cash Flow:
$7.27B
1W Performance:
-3.55%
1M Performance:
-4.46%
6M Performance:
-16.73%
1Y Performance:
-14.23%
1-Day Range:
$508.35
$516.48
1-Week Range:
$508.35
$536.21
52-Week Range:
$493.30
$627.88
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Name
Thermo Fisher Scientific Inc
Sector
Industry
Phone
(781) 622-1000
Address
168 THIRD AVENUE, WALTHAM, MA
Compare TMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
508.90 | 191.99B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
204.09 | 145.87B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
117.33 | 33.47B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IDXX
Idexx Laboratories Inc
|
406.29 | 33.04B | 3.90B | 887.87M | 798.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
181.43 | 31.99B | 15.41B | 1.37B | 2.11B | 7.50 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-23-24 | Initiated | Scotiabank | Sector Perform |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Oct-01-24 | Initiated | Stephens | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Mar-18-24 | Resumed | Citigroup | Neutral |
| Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-08-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-26-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-25-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-06-23 | Resumed | Citigroup | Buy |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| Jul-19-23 | Reiterated | Robert W. Baird | Outperform |
| Jul-13-23 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-04-23 | Reiterated | Barclays | Overweight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jan-26-22 | Resumed | Barclays | Overweight |
| Oct-20-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-16-21 | Initiated | The Benchmark Company | Buy |
| Mar-18-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Initiated | Goldman | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-14-20 | Initiated | Morgan Stanley | Overweight |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Jul-15-20 | Upgrade | Cleveland Research | Neutral → Buy |
| Jul-07-20 | Reiterated | Needham | Buy |
| Apr-23-20 | Reiterated | Needham | Buy |
| Jan-31-20 | Reiterated | Needham | Buy |
| Jan-22-20 | Initiated | Credit Suisse | Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-25-19 | Reiterated | Needham | Buy |
| Jul-16-19 | Downgrade | Needham | Strong Buy → Buy |
| May-30-19 | Initiated | Wolfe Research | Outperform |
| May-23-19 | Reiterated | Needham | Strong Buy |
| Apr-22-19 | Reiterated | Needham | Strong Buy |
| Apr-16-19 | Reiterated | BofA/Merrill | Buy |
View All
Thermo Fisher Scientific Inc Stock (TMO) Latest News
Faces of HR: Thermo Fisher Scientific's Pallavi Srivastava on the importance of fungibility of skills within the workforce - Human Resources Online
New exhibit at Discovery Center showcases lab techniques for kids - MyStateline.com
Market Whales and Their Recent Bets on TMO Options - Benzinga
CRDMO Market Research 2025: A Highly Competitive $328 - GlobeNewswire
Exosomes Drug Market Detailed In New Research Report 2025 | Thermo Fisher Scientific, Inc., Bio-Techne - openPR
Thermo Fisher Scientific’s CHF1.425 Billion Bond Issuance - Global Legal Chronicle
Laboratory Equipment and Disposables Market is expected - openPR
Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.
Gas Chromatograph Market Industry Report 2025, with Profiles of Agilent, Shimadzu, Thermo Fisher Scientific, PerkinElmer, Shandong Huifen, Shanghai Kechuang, Zhejiang Fuli Analytical Instrument & BFRL - GlobeNewswire Inc.
Thermo Fisher Executive Cashes In on Stock Sale! - TipRanks
Thermo Fisher Scientific SVP sells $2.01 million in stock By Investing.com - Investing.com Australia
Thermo Fisher Scientific SVP sells $2.01 million in stock - Investing.com
Neurological Biomarkers: Global Market Review 2020-2024 and - GlobeNewswire
Molecular Breeding Market Insights, Competitive Intelligence and Growth Forecast 2025-2030 - GlobeNewswire Inc.
Mexico In-Vitro Diagnostics Market Deep Research 2025-2032 | Thermo Fisher Scientific Inc., Siemens Healthineers - openPR
Thermo Fisher Scientific: Not Living Up To Its Positioning (NYSE:TMO) - Seeking Alpha
WilmerHale Advises Thermo Fisher on its CHF 1.425 Billion Offering of Bonds - WilmerHale
Cas Nuclease Market Size, Forecast 2031 by Key Companies- Thermo - openPR
Thermo Fisher Scientific Inc. to Host Earnings Call - ACCESS Newswire
Insider Selling: Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Sells $5,166,700.00 in Stock - Defense World
A New Era of STEMOptimization for Advanced Materials Discovery - AZoM
Lung Cancer Diagnostics Market Forecast Report and - GlobeNewswire
Lung Cancer Diagnostics Market Forecast Report and Competitive Analysis 2025-2033 Featuring llumina, Abbott, Thermo Fisher Scientific, QIAGEN, Roche, Sanofi, Agilent Technologies, bioMerieux - Yahoo Finance
Unit Dose Manufacturing Industry Report 2025-2030: Market - GlobeNewswire
Unit Dose Manufacturing Industry Report 2025-2030: Market to Cross $150.6 Billion Led by Catalent, Unither Pharmaceuticals, and Thermo Fisher Scientific - Yahoo Finance
Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace
Thermo Fisher Scientific: Strong Q4, Strategic M&A, And Poised For Growth In Life Sciences - Seeking Alpha
Thermo Fisher Scientific CEO sells $9.3 million in stock By Investing.com - Investing.com South Africa
Thermo Fisher Scientific CEO sells $9.3 million in stock - Investing.com India
Here’s Why Thermo Fisher Scientific (TMO) Fell in Q4 - MSN
Deutsche Bank Adjusts Price Target on Thermo Fisher Scientific to $615 From $630, Keeps Buy Rating - Marketscreener.com
Multiplex Assay Market Generated Opportunities, Future Scope - openPR
Thermo Fisher Scientific Inc. stock rises Wednesday, outperforms market - MarketWatch
Ryan Snyder On AI And Digital Innovation At Thermo Fisher Scientific - Forbes
Invest with Confidence: Intrinsic Value Unveiled of Thermo Fisher Scientific Inc - Yahoo Finance
Thermo Fisher Scientific EVP Michael Shafer sells $945,037 in stock - Investing.com
Thermo Fisher Scientific EVP Michael Shafer sells $945,037 in stock By Investing.com - Investing.com UK
Thermo Fisher Scientific Inc. (TMO): A Bull Case Theory - Insider Monkey
Assessment of the $1.41 Billion Peptide Synthesis Industry - GlobeNewswire
Assessment of the $1.41 Billion Peptide Synthesis Industry 2025-2029: Dominated by Bachem, Thermo Fisher Scientific, Merck, GenScript, and CEM Corporation - Yahoo Finance
Global Microbiological Testing of Water Market to Reach $2.3 Billion by 2027, Dominated by Tech Giants 3M - EIN News
Global Microbiological Testing of Water Market to Reach - GlobeNewswire
Citigroup Adjusts Price Target on Thermo Fisher Scientific to $570 From $650, Maintains Neutral Rating - Marketscreener.com
Ultrasonic Aspirator Market Detailed In New Research Report - openPR
February M&A deals: Thermo Fisher, Novartis, and CyberArk Software - The Business Journals
Is Thermo Fisher Scientific Stock Underperforming the S&P 500? - Nasdaq
High-Throughput Screening Technology Analysis and Global - GlobeNewswire
Is Thermo Fisher Scientific Stock Underperforming The S&P 500? - Barchart
US-based Thermo Fisher Scientific to expand India manufacturing base: Ashwini Vaishnaw - MSN
Thermo Fisher Scientific to Acquire Purification and Filtration Business - MedTech Intelligence
Thermo Fisher Expands Horizons with Bold $4.1 Billion Acquisition - Clinique Bio
Thermo Fisher Scientific Inc Stock (TMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):